Talk! with Audrey

Mike McDaniel, an ACTIV-2 treatment study clinical trial participant talks about his personal experience in the ACTIV-2 treatment study clinical trial and why he feels it's important to consider volunteering to diversify the study. His family of five, were all Covid positive.   In April, 2020 the National Institutes of Health (NIH) announced Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding development of the most promising treatments and vaccines. You’ve no doubt heard about the vaccine to help prevent covid 19 infections,  but there is also a need to find effective treatments for people with Covid 19. In this series you'll hear first hand from an infectious disease specialist, a community advisor and a clinical trial participant about the need to diversify the study to help save lives.